InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
2
T+90 hit rate
100%
T+90 mean return
+58.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by GILL DAVID N, Director. Officer active across 4 companies, notably Strongbridge Biopharma plc. In total, 17 filings have been recorded. Breakdown: 0 buy · 2 sells. Total volume traded: €110k. History available since 14 May 2021. The latest transaction was disclosed on 7 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations17 total
7,364 shares0Common StockSEC:0001570562-25-000039:0
3,495 shares0Common StockSEC:0001104659-24-071399:0
3,643 shares@ US$12.724739.0% of flowCommon StockSEC:0001570562-24-000090:0
6,464 shares0Common StockSEC:0001570562-24-000024:0
2,330 shares0Common StockSEC:0001104659-23-070043:0
8,293 shares0Common StockSEC:0001570562-23-000021:0
5,313 shares@ US$13.0970.016% mcap100.0% of flowCommon StockSEC:0001570562-22-000104:0
15,568 shares0Common StockSEC:0001570562-22-000049:0
15,568 shares0Common StockSEC:0001570562-22-000049
78,058 sharesOrdinary SharesSEC:0001179110-21-009277
78,058 sharesOrdinary SharesSEC:0001179110-21-009277:0
17,763 shares@ US$2.0629.9% of flowOrdinary SharesSEC:0001179110-21-009218:0
17,763 shares@ US$2.06100.0% of flowOrdinary SharesSEC:0001179110-21-009218
40,000 shares0Ordinary SharesSEC:0001179110-21-005555
40,000 shares0Ordinary SharesSEC:0001179110-21-005555:0
19,075 shares@ US$2.3535.1% of flowOrdinary SharesSEC:0001179110-21-005441
19,075 shares@ US$2.3535.1% of flowOrdinary SharesSEC:0001179110-21-005441:0
17 of 17 declarations
About GILL DAVID N
David N. Gill serves as a Board Member at Strongbridge Biopharma plc and Evolus, Inc. In this role, he oversees the operations of these companies and participates in strategic decision-making. His expertise in the biopharmaceutical sector allows him to provide significant contributions to the board.
